Prognostic Significance of Ribosome-related Genes Signature in Diffuse Large B Cell Lymphoma.

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Diffuse large B-cell lymphoma (DLBCL) has a poor prognosis for a significant portion of patients treated with standard R-CHOP therapy.
• Accurate risk stratification and targeted therapies are urgently needed for DLBCL patients.
• Ribosome-related genes (RibGs) are increasingly implicated in cellular proliferation and tumorigenesis, suggesting their potential role in DLBCL.

Purpose of the Study:

• To construct and validate a prognostic model for DLBCL patients utilizing ribosome-related genes (RibGs).
• To identify novel biomarkers for risk classification and potential therapeutic targets in DLBCL.

Main Methods:

• Screened differentially expressed RibGs between healthy B cells and DLBCL cells.
• Employed univariate Cox, LASSO, and multivariate Cox regression analyses to build a 15-RibG prognostic model.
• Validated the model using Cox regression, Kaplan-Meier survival analysis, ROC curves, and nomograms in training and validation cohorts.

Main Results:

• The RibGs-based model demonstrated reliable predictive capability for DLBCL prognosis.
• High-risk patients exhibited upregulated pathways associated with innate immune responses, including interferon and complement.
• A nomogram incorporating age, gender, IPI score, and risk score was developed; high-risk patients showed differential drug sensitivity.

Conclusions:

• This study presents the first prognostic model for DLBCL based on RibGs, offering a new perspective on DLBCL treatment.
• The RibGs model can serve as a valuable supplement to the International Prognostic Index (IPI) for DLBCL risk classification.
• Targeting NLE1, a specific RibG, inhibited DLBCL cell proliferation, indicating its therapeutic potential.